Lantern Financial Statements From 2010 to 2024

LTRN Stock  USD 5.77  0.22  3.67%   
Lantern Pharma financial statements provide useful quarterly and yearly information to potential Lantern Pharma investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Lantern Pharma financial statements helps investors assess Lantern Pharma's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Lantern Pharma's valuation are summarized below:
Market Capitalization
64.3 M
Earnings Share
(1.47)
We have found one hundred twenty available fundamental ratios for Lantern Pharma, which can be analyzed and compared to other ratios and to its peers in the industry. Self-guided Investors are advised to check Lantern Pharma's last-minute fundamentals against the trend between 2010 and 2024 to make sure the company can sustain itself down the road. As of the 19th of April 2024, Market Cap is likely to grow to about 92.6 M, while Enterprise Value is likely to drop about 23.5 M.
Check Lantern Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Lantern main balance sheet or income statement drivers, such as Depreciation And Amortization of 183.6 K, Interest Expense of 246.8 K or Selling General Administrative of 6.3 B, as well as many exotic indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 1.19. Lantern financial statements analysis is a perfect complement when working with Lantern Pharma Valuation or Volatility modules.
  
This module can also supplement Lantern Pharma's financial leverage analysis and stock options assessment as well as various Lantern Pharma Technical models . Check out the analysis of Lantern Pharma Correlation against competitors.
To learn how to invest in Lantern Stock, please use our How to Invest in Lantern Pharma guide.

Lantern Pharma Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets36.4 M43.6 M15.9 M
Slightly volatile
Other Current Liabilities2.6 B2.5 B343.2 M
Slightly volatile
Total Current Liabilities1.7 M2.7 M1.1 M
Slightly volatile
Property Plant And Equipment Net294.4 K280.4 K63.9 K
Slightly volatile
Accounts Payable1.6 M2.5 M727.7 K
Slightly volatile
Cash24.1 M21.9 M10.6 M
Slightly volatile
Non Current Assets Total363.2 K306.3 K158.8 K
Slightly volatile
Non Currrent Assets Other47.8 K25.9 K29.6 K
Slightly volatile
Cash And Short Term Investments34.5 M41.3 M15.1 M
Slightly volatile
Common Stock Total Equity9299777.9 K
Slightly volatile
Common Stock Shares Outstanding9.4 M10.8 M7.4 M
Slightly volatile
Liabilities And Stockholders Equity36.4 M43.6 M15.9 M
Slightly volatile
Capital Surpluse115.5 M110 M32.9 M
Slightly volatile
Other Stockholder Equity61 M96.3 M28.4 M
Slightly volatile
Total Liabilities1.8 M2.7 M1.1 M
Slightly volatile
Total Current Assets36.1 M43.3 M15.8 M
Slightly volatile
Capital StockK1.1 K13.3 K
Slightly volatile
Common StockK1.1 K7.9 K
Slightly volatile
Property Plant Equipment65.8 K55.2 K30.5 K
Slightly volatile
Other Assets19.5 K20.6 K205.8 K
Very volatile
Other Current Assets1.7 M1.2 M627.1 K
Slightly volatile
Deferred Long Term Liabilities116.9 K91.1 K161.4 K
Slightly volatile
Property Plant And Equipment Gross294.4 K280.4 K66.4 K
Slightly volatile
Short and Long Term Debt Total165.2 K234.5 K123.4 K
Slightly volatile
Long Term Debt86.8 K97.7 K106.3 K
Slightly volatile
Non Current Liabilities Other86.8 K97.7 K106.3 K
Slightly volatile
Net Receivables598.8 K860 K281.5 K
Slightly volatile
Short Term Debt138.6 K173 K145.9 K
Pretty Stable

Lantern Pharma Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Selling General Administrative6.3 BB819.5 M
Slightly volatile
Other Operating Expenses10.1 M17.9 M5.3 M
Slightly volatile
Research Development12.5 M11.9 M3.3 M
Slightly volatile
Total Operating Expenses10 M17.7 M5.2 M
Slightly volatile
Cost Of Revenue95 K174.8 K36.1 K
Slightly volatile
Non Recurring1.8 MM2.2 M
Slightly volatile
Selling And Marketing Expenses4.8 B5.4 B5.9 B
Slightly volatile

Lantern Pharma Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Net Borrowings86.8 K97.7 K106.3 K
Slightly volatile
Stock Based Compensation863.9 K1.1 M470.7 K
Slightly volatile
Begin Period Cash Flow20.6 M37.7 M9.5 M
Slightly volatile
Capital Expenditures16.4 K18.7 K10.1 K
Slightly volatile
End Period Cash Flow24.4 M21.9 M10.7 M
Slightly volatile
Change To Netincome2.1 MM665.6 K
Slightly volatile
Change To Liabilities607.8 K667.4 K306.6 K
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Invested Capital0.00540.00570.068
Slightly volatile
Average Payables416.7 K468.7 K510.4 K
Slightly volatile
Payables Turnover0.07330.06980.0189
Slightly volatile
Cash Per Share2.53.80941.4543
Slightly volatile
Capex To Operating Cash Flow0.00230.00130.0025
Slightly volatile
Days Payables OutstandingK5.2 K78.8 K
Slightly volatile
Income Quality0.70.89880.7875
Slightly volatile
Net Debt To EBITDA1.581.2261.0351
Slightly volatile
Current Ratio14.4316.18318.5443
Slightly volatile
Graham Number6.1611.17913.73
Slightly volatile
Debt To Equity0.00540.00570.068
Slightly volatile
Interest Debt Per Share0.02050.02160.3434
Slightly volatile
Debt To Assets0.00510.00540.0648
Slightly volatile
Days Of Payables OutstandingK5.2 K78.8 K
Slightly volatile
Ebt Per Ebit1.050.89280.9809
Very volatile
Long Term Debt To Capitalization0.00140.00150.0366
Slightly volatile
Total Debt To Capitalization0.00540.00570.0373
Slightly volatile
Debt Equity Ratio0.00540.00570.068
Slightly volatile
Quick Ratio13.8915.7438.2355
Slightly volatile
Dividend Paid And Capex Coverage Ratio421766427
Slightly volatile
Net Income Per E B T1.091.141.0101
Slightly volatile
Cash Ratio10.898.19136.5337
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.11.00131.009
Slightly volatile
Capital Expenditure Coverage Ratio421766427
Slightly volatile
Debt Ratio0.00510.00540.0648
Slightly volatile

Lantern Pharma Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap92.6 M46.4 M89.4 M
Slightly volatile
Enterprise Value23.5 M24.7 M75.9 M
Slightly volatile

Lantern Fundamental Market Drivers

Cash And Short Term Investments41.3 M

Lantern Upcoming Events

18th of March 2024
Upcoming Quarterly Report
View
14th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
18th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Lantern Pharma Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Lantern Pharma income statement, its balance sheet, and the statement of cash flows. Lantern Pharma investors use historical funamental indicators, such as Lantern Pharma's revenue or net income, to determine how well the company is positioned to perform in the future. Although Lantern Pharma investors may use each financial statement separately, they are all related. The changes in Lantern Pharma's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Lantern Pharma's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Lantern Pharma Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Lantern Pharma. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue-2.5 B-2.4 B
Total Revenue 0.00  0.00 
Cost Of Revenue174.8 K95 K
Stock Based Compensation To Revenue 0.00  0.00 
Sales General And Administrative To Revenue 0.00  0.00 
Research And Ddevelopement To Revenue 0.00  0.00 
Capex To Revenue 0.00  0.00 
Revenue Per Share 0.00  0.00 
Ebit Per Revenue 0.00  0.00 
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Lantern Pharma in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Lantern Pharma's short interest history, or implied volatility extrapolated from Lantern Pharma options trading.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Lantern Pharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Lantern Pharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Lantern Pharma Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Lantern Pharma Stock:
Check out the analysis of Lantern Pharma Correlation against competitors.
To learn how to invest in Lantern Stock, please use our How to Invest in Lantern Pharma guide.
You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.

Complementary Tools for Lantern Stock analysis

When running Lantern Pharma's price analysis, check to measure Lantern Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lantern Pharma is operating at the current time. Most of Lantern Pharma's value examination focuses on studying past and present price action to predict the probability of Lantern Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lantern Pharma's price. Additionally, you may evaluate how the addition of Lantern Pharma to your portfolios can decrease your overall portfolio volatility.
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
USA ETFs
Find actively traded Exchange Traded Funds (ETF) in USA
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Transaction History
View history of all your transactions and understand their impact on performance
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
AI Portfolio Architect
Use AI to generate optimal portfolios and find profitable investment opportunities
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
ETFs
Find actively traded Exchange Traded Funds (ETF) from around the world
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Is Lantern Pharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lantern Pharma. If investors know Lantern will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lantern Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.47)
Return On Assets
(0.22)
Return On Equity
(0.33)
The market value of Lantern Pharma is measured differently than its book value, which is the value of Lantern that is recorded on the company's balance sheet. Investors also form their own opinion of Lantern Pharma's value that differs from its market value or its book value, called intrinsic value, which is Lantern Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lantern Pharma's market value can be influenced by many factors that don't directly affect Lantern Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lantern Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Lantern Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lantern Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.